Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism.

Akamatsu S, Hayes CN, Tsuge M, Murakami E, Hiraga N, Abe H, Miki D, Imamura M, Ochi H, Chayama K; Hiroshima Liver Study Group.

J Viral Hepat. 2015 Feb;22(2):166-74. doi: 10.1111/jvh.12275. Epub 2014 Jun 16.

PMID:
24930407
2.

ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type.

Matsuura K, Tanaka Y, Watanabe T, Fujiwara K, Orito E, Kurosaki M, Izumi N, Sakamoto N, Enomoto N, Yatsuhashi H, Kusakabe A, Shinkai N, Nojiri S, Joh T, Mizokami M.

J Viral Hepat. 2014 Jul;21(7):466-74. doi: 10.1111/jvh.12171. Epub 2013 Sep 3.

PMID:
24750345
3.

ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C.

Morio K, Imamura M, Kawakami Y, Nakahara T, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Aikata H, Hayes CN, Makokha GN, Ochi H, Amano H, Arataki K, Moriya T, Ito H, Tsuji K, Kohno H, Waki K, Tamura T, Nakamura T, Chayama K; Hiroshima Liver Study Group.

J Gastroenterol. 2017 Jun;52(6):746-753. doi: 10.1007/s00535-016-1279-9. Epub 2016 Nov 7.

PMID:
27822709
4.

Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection.

Seto WK, Tsang OT, Liu K, Chan JM, Wong DK, Fung J, Lai CL, Yuen MF.

J Viral Hepat. 2013 Jul;20(7):470-7. doi: 10.1111/jvh.12047. Epub 2013 Apr 12.

PMID:
23730840
5.

Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices.

Di Marco V, Calvaruso V, Grimaudo S, Ferraro D, Pipitone RM, Di Stefano R, Craxì A.

J Viral Hepat. 2013 Feb;20(2):113-21. doi: 10.1111/j.1365-2893.2012.01637.x. Epub 2012 Jul 25.

PMID:
23301546
6.

Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy.

Azakami T, Hayes CN, Sezaki H, Kobayashi M, Akuta N, Suzuki F, Kumada H, Abe H, Miki D, Tsuge M, Imamura M, Kawakami Y, Takahashi S, Ochi H, Nakamura Y, Kamatani N, Chayama K.

J Med Virol. 2011 Jun;83(6):1048-57. doi: 10.1002/jmv.22069.

PMID:
21503919
7.

Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy.

Ogawa E, Furusyo N, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group.

J Hepatol. 2013 Oct;59(4):667-74. doi: 10.1016/j.jhep.2013.05.017. Epub 2013 May 23.

PMID:
23707372
8.

Relationship between inosine triphosphate genotype and outcome of extended therapy in hepatitis C virus patients with a late viral response to pegylated-interferon and ribavirin.

Hai H, Tamori A, Enomoto M, Morikawa H, Uchida-Kobayashi S, Fujii H, Hagihara A, Kawamura E, Thuy le TT, Tanaka Y, Kawada N.

J Gastroenterol Hepatol. 2014 Jan;29(1):201-7. doi: 10.1111/jgh.12376.

PMID:
23980585
9.

Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.

Suzuki F, Suzuki Y, Akuta N, Sezaki H, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y, Ikeda K, Kobayashi M, Chayama K, Kamatani N, Nakamura Y, Miyakawa Y, Kumada H.

Hepatology. 2011 Feb;53(2):415-21. doi: 10.1002/hep.24058. Epub 2011 Jan 18.

PMID:
21246582
10.

Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy.

Tahata Y, Hiramatsu N, Oze T, Urabe A, Morishita N, Yamada R, Yakushijin T, Hosui A, Oshita M, Kaneko A, Hagiwara H, Mita E, Ito T, Yamada Y, Inada M, Katayama K, Tamura S, Imai Y, Hikita H, Sakamori R, Yoshida Y, Tatsumi T, Hayashi N, Takehara T.

J Med Virol. 2016 Oct;88(10):1776-84. doi: 10.1002/jmv.24528. Epub 2016 Mar 29.

PMID:
26991414
11.

Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C.

Fujino H, Imamura M, Nagaoki Y, Kawakami Y, Abe H, Hayes CN, Kan H, Fukuhara T, Kobayashi T, Masaki K, Ono A, Nakahara T, Honda Y, Naeshiro N, Urabe A, Yokoyama S, Miyaki D, Murakami E, Kawaoka T, Hiraga N, Tsuge M, Hiramatsu A, Hyogo H, Aikata H, Takahashi S, Miki D, Ochi H, Ohishi W, Chayama K; Hiroshima Liver Study Group.

J Gastroenterol. 2014 Dec;49(12):1548-56. doi: 10.1007/s00535-013-0924-9. Epub 2013 Dec 21.

PMID:
24362944
12.

The relationship between ITPA rs1127354 polymorphisms and efficacy of antiviral treatment in Northeast Chinese CHC patients.

Liu Z, Wang S, Qi W, Wang X, Sun D, Wang H, Zhang Y, Li Z, Zhu L, Zhao P, Guo H, Zhou C, Wang J.

Medicine (Baltimore). 2017 Jul;96(29):e7554. doi: 10.1097/MD.0000000000007554.

13.

IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C.

Chayama K, Hayes CN, Abe H, Miki D, Ochi H, Karino Y, Toyota J, Nakamura Y, Kamatani N, Sezaki H, Kobayashi M, Akuta N, Suzuki F, Kumada H.

J Infect Dis. 2011 Jul 1;204(1):84-93. doi: 10.1093/infdis/jir210.

14.

Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir.

Boglione L, De Nicolò A, Cusato J, Cariti G, Di Perri G, D'Avolio A.

J Viral Hepat. 2014 Apr;21(4):260-3. doi: 10.1111/jvh.12170. Epub 2013 Sep 2.

PMID:
24597694
15.

Increase in platelet count based on inosine triphosphatase genotype during interferon beta plus ribavirin combination therapy.

Nomura H, Miyagi Y, Tanimoto H, Yamashita N, Ito K, Masaki N, Mizokami M.

J Gastroenterol Hepatol. 2012 Sep;27(9):1461-6. doi: 10.1111/j.1440-1746.2012.07171.x.

PMID:
22554247
16.

Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin.

Kurosaki M, Tanaka Y, Tanaka K, Suzuki Y, Hoshioka Y, Tamaki N, Kato T, Yasui Y, Hosokawa T, Ueda K, Tsuchiya K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Matsuura K, Sugauchi F, Enomoto N, Nishida N, Tokunaga K, Mizokami M, Izumi N.

Antivir Ther. 2011;16(5):685-94. doi: 10.3851/IMP1796.

PMID:
21817190
17.

Safety and efficacy of partial splenic embolization in telaprevir-based triple therapy for chronic hepatitis C.

Kondo C, Atsukawa M, Tsubota A, Shimada N, Abe H, Itokawa N, Nakagawa A, Fukuda T, Matsushita Y, Nakatsuka K, Kawamoto C, Iwakiri K, Aizawa Y, Sakamoto C.

Intern Med. 2015;54(2):119-26. doi: 10.2169/internalmedicine.54.3066. Epub 2015 Jan 15.

18.

SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir.

Milazzo L, Peri AM, Mazzali C, Magni C, Calvi E, De Nicolò A, Clementi E, Cheli S, D'Avolio A, Antinori S, Falvella FS.

J Antimicrob Chemother. 2015 Apr;70(4):1155-60. doi: 10.1093/jac/dku519. Epub 2015 Jan 11.

PMID:
25583751
19.

Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients.

Ahmed WH, Furusyo N, Zaky S, Eldin AS, Aboalam H, Ogawa E, Murata M, Hayashi J.

World J Gastroenterol. 2013 Mar 7;19(9):1387-95. doi: 10.3748/wjg.v19.i9.1387.

20.

Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment.

Ampuero J, Del Campo JA, Rojas L, Calleja JL, Cabezas J, Lens S, Crespo J, Forns X, Andrade RJ, Fernández I, Buti M, Millán R, Romero-Gómez M.

J Clin Virol. 2015 Jul;68:56-60. doi: 10.1016/j.jcv.2015.05.010. Epub 2015 May 14.

PMID:
26071337

Supplemental Content

Support Center